Goodwin Partner Greg Demske, from Washington, DC, practices in Complex Litigation & Dispute Resolution, Healthcare, and more.

Greg Demske

Partner
Greg Demske
Washington, DC
+1 202 346 4489

Greg Demske is a partner in Goodwin’s Healthcare and Life Sciences practices. Prior to joining Goodwin in 2023, Greg served as chief counsel to the HHS Inspector General for 10 years and as an OIG attorney for over 30 years. With his deep and broad experience leading all OIG legal work and teaming with the Department of Justice (DOJ) on hundreds of cases, Greg advises clients based on his understanding of how the government interprets and enforces the Anti-Kickback Statute (AKS) and the False Claims Act (FCA). Greg counsels and represents life sciences and healthcare companies, executives, boards, and investors on the full range of compliance and enforcement matters.

Greg works with clients to structure business practices to reduce AKS risks, respond to internal or external compliance allegations, lead internal investigations, assess and mitigate compliance risks in mergers and acquisitions, provide expert compliance advice, submit and resolve voluntary disclosures, obtain OIG advisory opinions, and advocate, negotiate, and litigate against the DOJ, OIG, qui tam relators, and others in FCA and other enforcement cases.

Professional Activities

Greg is a Fellow of the American Health Law Association (AHLA).

Professional Experience

  • Successfully self-disclosed and resolved FCA claims against a health system regarding Medicare Advantage diagnosis coding. In re The Villages Health System, LLC, No. 25-04156 (LVV) (Bankr. M.D. Fla. 2026)
  • Obtained a favorable OIG advisory opinion regarding medical device manufacturer subsidies of cost-sharing in a clinical study. OIG Advisory Opinion 26-05
  • As an independent compliance expert, advises the board of the US subsidiary of a global medical device and pharmaceutical company
  • Successfully resolved OIG civil monetary penalty (CMP) case regarding drug price reporting for Solco Healthcare US
  • Represents clinical laboratory before DOJ in self-disclosed matter related to improper coding and billing
  • Represents medical device company in DOJ investigation of AKS violations and negotiations with OIG
  • Represented behavioral health provider in FCA investigation
  • As OIG Chief Counsel (2012-2022), led 130-person office responsible for providing all legal services to OIG, including:
    • Recommendations to DOJ in all HHS-related qui tams on intervention, litigation, and settlement
    • Negotiation and monitoring of Corporate Integrity Agreements (CIAs)
    • Exclusions from participation in federal health care programs
    • CMPs for fraud and other misconduct
    • Review and settlement of matters submitted under the OIG self-disclosure protocol
    • AKS safe harbor regulations
    • Advisory opinions on AKS and other OIG remedies
    • Guidance to industry on risk areas and voluntary compliance efforts
    • Legal advice to OIG on audits, evaluations, and investigations
  • At OIG, represented HHS on hundreds of FCA cases and dozens of CIAs and litigated CMP cases before administrative law judges
  • During his OIG career, served on details as a Special Assistant U.S. Attorney at the U.S. Attorney’s Office for the District of Columbia and as Acting Principal Deputy Inspector General

Credentials

Education

JD1990

The Ohio State University College of Law

BS1986

Miami University

Admissions

Bars

  • District of Columbia

Recognition & Awards

Greg was the 2025 recipient of the AHLA Patricia T. Meador Leadership Award, recognizing exceptional commitment to fraud and compliance education and mentoring.

In 2025, Greg was named a Fellow of the American Health Law Association.

Greg was named as a Recommended Lawyer for his work in Healthcare: Service Providers by The Legal 500 US in 2024 and 2026.

During his government career, Greg received the Attorney General’s Award for Fraud Prevention, the HHS Secretary’s Award for Distinguished Service, and multiple other awards.

THOUGHT LEADERSHIP

Greg frequently presents on topics related to healthcare and life sciences fraud enforcement and compliance. In addition to being a public speaker before multiple bar and compliance associations, Greg has presented to and engaged with healthcare and life science industry groups in many public and private settings.

Select Presentations

  • “Big and Small MedTech Companies in the Enforcement Crosshairs: Are You Ready?” AdvaMed MedTech Conference, October 19, 2026
  • “Investigations, Enforcement and Prosecutions Roundtable,” Pharmaceutical and Medical Device Ethics and Compliance Congress, October 15, 2026
  • “Compliance Risks and Challenges in Small and Emerging Life Sciences Companies,” Pharmaceutical and Medical Device Ethics and Compliance Congress, October 14, 2026
  • “AI as Evidence in Reimbursement: Audits, Investigations, Litigation, and Liability,” AHLA Annual Meeting, July 1, 2026
  • “Enforcement Insights: Advanced Strategies to Minimize Risk in Health Care Compliance,” AHLA Annual Meeting, June 30, 2026
  • “Hot Topics in Federal Health Care Enforcement and Compliance,” HCCA Compliance Institute, April 29, 2026
  • “The Medicare Advantage ICPG: What it Says and What it Means for the Industry,” AHLA Webinar, March 23, 2026
  • “Stark Law, Anti-Kickback and EKRA Enforcement Developments,” ABA White Collar Crime Institute, March 11, 2026
  • “Compliance Enforcement and Regulatory Developments in 2025,” HCCA Enforcement Compliance Conference, October 29, 2025
  • “Cooperation and Self-Disclosure: DOJ, OIG, and CMS,” HCCA Enforcement Compliance Conference, October 29, 2025
  • “Anti-Kickback, Physician Self-Referral (Stark) and CMP Bootcamp,” AHLA Fraud and Compliance Forum, October 8, 2025
  • “Top Regulatory and Enforcement Developments You Should Know About in 2025,” HCCA Compliance Institute, April 30, 2025
  • “Hot Topics in Fraud and Abuse 2025,” AHLA Institute on Medicare and Medicaid Payment Issues, March 26, 2025
  • “Fraud and Compliance Year in Review (2024): Looking Back, Planning Ahead,” AHLA Webinar, February 5, 2025
  • “New OIG and DOJ Compliance Guidance for Healthcare Providers,” Strafford CLE Webinar, January 29, 2025
  • “Anti-Kickback Statute and EKRA Primer,” AHLA Fundamentals of Health Law, November 18, 2024
  • “Physician Self-Referral Law vs Anti-Kickback Statute,” AHLA Fundamentals of Health Law, November 18, 2024
  • “Investigations, Enforcement and Prosecutions Roundtable,” Pharmaceutical and Medical Device Ethics and Compliance Congress, October 29, 2024
  • “Top Federal Healthcare Regulatory, Guidance, and Legal Developments,” HCCA Boston Regional Compliance Conference, September 13, 2024
  • “Defense Perspective Session,” National Association of Medicaid Fraud Control Units, June 27, 2024 
  • “OIG Compliance Program Guidance Reboot; What the Health Care Industry Should Know,” AHLA Webinar, May 15, 2024
  • “Enforcement and Compliance in Laboratory Services,” ABA Institute on Health Care Fraud, May 3, 2024
  • “Federal Administrative Enforcement: Suspensions, Exclusions, and Civil Money Penalties,” ABA Institute on Health Care Fraud, May 3, 2024
  • “The Legacy of Enforcement of the Anti-Kickback Statute,” ABA Institute on Health Care Fraud, May 1, 2024
  • “Update on Stark, Anti-kickback and EKRA Developments,” HCCA Compliance Institute, April 17, 2024
  • “Top Regulatory and Enforcement Developments You Should Know About in 2024,” HCCA Compliance Institute, April 16, 2024
  • “2023 OIG and DOJ Compliance Guidance for Healthcare Providers,” Strafford CLE Webinar, January 24, 2024
  • “Criminal and Civil Stark and Anti-Kickback Cases,” Georgia State Bar Association Health Care Fraud Seminar, December 7, 2023
  • “Anti-Kickback Statute and EKRA Primer,” AHLA Fundamentals of Health Law, November 6, 2023
  • “Physician Self-Referral Law vs Anti-Kickback Statute,” AHLA Fundamentals of Health Law, November 6, 2023
  • “Reflections on the Role of the False Claims Act as a Major Force in the Regulation of the Pharmaceutical and Medical Device Industries,” Pharmaceutical and Medical Device Ethics and Compliance Congress, October 26, 2023
  • “The Rising Stakes of Data Governance and How Companies are Responding,” Pharmaceutical and Medical Device Ethics and Compliance Congress, October 25, 2023
  • “Chief Compliance Officer Lightning Round,” AdvaMed Medtech Conference, October 11, 2023
  • “Trends in False Claims Act Litigation, OIG Audits, and Other Risk Areas,” CompliancePalooza, October 3, 2023
  • “The Current State of RA Litigation and Risk Areas for MA Plans, Physician Groups, Vendors and Downstream Entities,” RISE West 2023, August 29, 2023
  • “Federal Administrative Enforcement: Suspensions, Exclusions and Civil Money Penalties,” American Bar Association (ABA) Institute on Health Care Fraud, May 5, 2023
  • “Cooperation Credit and FCA Settlements – Is the Juice Worth the Squeeze?” Federal Bar Association webinar, May 3, 2023

Congressional Testimony

  • “Continuing Concerns with the Federal Select Agent Program: Department of Defense Shipments of Live Anthrax,” House of Representatives Committee on Energy and Commerce, Subcommittee on Oversight and Investigation, July 28, 2015
  • “Examining the Relationship Between the Medical Device Industry and Physicians,” Senate Special Committee on Aging, February 27, 2008
  • “Role of OIG in Identifying and Preventing Abuse of the Elderly,” Senate Special Committee on Aging, July 18, 2007

Articles